The mission of the Psychiatric Cell Map Initiative (PCMI) is to bridge the gap between the genome and clinic in the field of neuropsychiatric disorder research by systematically mapping the physical and genetic interaction networks underlying these disorders, including autism spectrum disorders, Tourette disorder, epilepsy, intellectual disability, and schizophrenia. This will form a key resource ...
The mission of the Psychiatric Cell Map Initiative (PCMI) is to bridge the gap between the genome and clinic in the field of neuropsychiatric disorder research by systematically mapping the physical and genetic interaction networks underlying these disorders, including autism spectrum disorders, Tourette disorder, epilepsy, intellectual disability, and schizophrenia. This will form a key resource for precision medicine.
In September 2018, the PCMI received its first award, the collaborative U01 in the Convergent Neurosciences Consortium of NIMH, to study autism spectrum disorder (ASD).
Read more
PCMI Investigators can now share data easily using the NDEx data interchange.
Read More
PCMI is an interdisciplinary collaborative research effort to study cell mapping of neuropsychiatric disorders.
